Skip to main content
SpringerLink
Log in

111In and 131I labeled nimotuzumabs for targeted radiotherapy of a murine model of glioma

  • Published:
Journal of Radioanalytical and Nuclear Chemistry Aims and scope Submit manuscript

Abstract

The anticancer effect of [111In]In-DOTA-nimotuzumab and [131I]I-ATE-nimotuzumab was systematically investigated in vivo. [111In]In-DOTA-nimotuzumab mainly distributed in tumor, liver and kidneys, which was proven by pathological sections, while cleavage of 131I from [131I]I-ATE-nimotuzumab caused major accumulation of blood and thyroid. Further therapy in vivo investigations suggested that [111In]In-DOTA-nimotuzumab has better tumor inhibition effect and prolonged the survival time significantly compared with [131I]I-ATE-nimotuzumab.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Watanabe N, Sawai H, Ogihara-Umeda I, Tanada S, Sasaki Y (2006) Molecular therapy of human neuroblastoma cells using Auger electrons of 111In-labeled N-myc antisense oligonucleotides. J Nucl Med 47:1670–1677

    CAS  PubMed  Google Scholar 

  2. Aghevlian S, Lu YJ, Winnik MA, Hedley DW, Reilly RM (2018) Panitumumab modified with metal-chelating polymers (MCP) complexed to 111In and 177Lu-An EGFR-targeted theranostic for pancreatic cancer. Mol Pharm 15:1150–1159

    Article  CAS  PubMed  Google Scholar 

  3. Rosenkranz AA, Slastnikova TA, Karmakova TA, Vorontsova MS, Morozova NB, Petriev VM, Abrosimov AS, Khramtsov YV, Lupanova TN, Ulasov AV, Yakubovskaya RI, Georgiev GP, Sobolev AS (2018) Antitumor activity of auger electron emitter 111In delivered by modular nanotransporter for treatment of bladder cancer with EGFR overexpression. Front Pharmacol 9:1331

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Liang RX, Liao ZH, Li FZ, Ma H, Liu WH, Chen XJ, Lan T, Yang YY, Liao JL, Yang JJ, Liu N (2022) In vitro anticancer ability of nano fluorescent 111In-MIL-68/PEG-FA on hela cells. Chem Eur J 28:e202104589

    Article  CAS  PubMed  Google Scholar 

  5. Hindie E, Zanotti-Fregonara P, Quinto MA, Morgat C, Champion C (2016) Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: implications for radiopharmaceutical therapy. J Nucl Med 57:759–764

    Article  CAS  PubMed  Google Scholar 

  6. Kassis AI (2011) Molecular and cellular radiobiological effects of Auger emitting radionuclides. Radiat Prot Dosim 143:241–247

    Article  CAS  Google Scholar 

  7. Tang Y, Liu WH, Li FZ, Chen L, Wang MS, Hu YJ, Liao ZH, Chen Y, Li SF, Liao JL, Yang JJ, Yang YY, Liu N (2019) Indium-111 labeled bleomycin for targeting diagnosis and therapy of liver tumor: optimized preparation, biodistribution and SPECT imaging with xenograft models. J Radioanal Nucl Chem 322:545–551

    Article  CAS  Google Scholar 

  8. Teunissen JM, Kwekkeboom DJ, de Jong M, Esser J-P, Valkema R, Krenning EP (2005) Peptide receptor radionuclide therapy. Best Pract Res Cl Ga 19:595–616

    Article  CAS  Google Scholar 

  9. Capello A, Krenning E, Bernard B, Reubi JC, Breeman W, de Jong M (2005) 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 32:1288–1295

    Article  CAS  PubMed  Google Scholar 

  10. Banerjee SR, Kumar V, Lisok A, Plyku D, Novakova Z, Brummet M, Wharram B, Barinka C, Hobbs R, Pomper MG (2019) Evaluation of 111In-DOTA-5D3, a surrogate SPECT imaging agent for radioimmunotherapy of prostate-specific membrane antigen. J Nucl Med 60:400–406

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Liao ZH, Li FZ, Tang Y, Liu WH, Gao J, Lan T, Yang JJ, Liao JL, Liu N, Yang YY (2021) Preliminary in vitro comparison of 111In and 131I labeled nimotuzumabs. J Radioanal Nucl Chem 328:527–537

    Article  CAS  Google Scholar 

  12. Kayano D, Kinuya S, Kayano D (2018) Current consensus on I-131 MIBG therapy. Nucl Med Mol Imaging 52:254–265

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Ma H, Li FZ, Shen GH, Cai HW, Liu WH, Lan T, Yang YY, Yang JJ, Liao JL, Liu N (2021) Synthesis and preliminary evaluation of 131I-labeled FAPI tracers for cancer theranostics. Mol Pharm 18:4179–4187

    Article  CAS  PubMed  Google Scholar 

  14. Kayano D, Kinuya S (2018) Current consensus on I-131 MIBG therapy. Nucl Med Mol Imaging 52:254–265

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Gao J, Liao ZH, Liu WH, Hu YJ, Ma H, Xia LT, Li FZ, Lan T, Yang YY, Yang JJ, Liao JL, Liu N (2021) Simple and efficient method for producing high radionuclidic purity 111In using enriched 112Cd target. Appl Radiat Isot 176:109828

    Article  CAS  PubMed  Google Scholar 

  16. Li FZ, Yang YY, Liao JL, Liu N (2022) Recent progress of astatine-211 in endoradiotherapy: great advances from fundamental properties to targeted radiopharmaceuticals. Chin Chem Lett 33:3325–3338

    Article  CAS  Google Scholar 

  17. Ma H, Li FZ, Shen GH, Pan LL, Liu WH, Liang RX, Lan T, Yang YY, Yang JJ, Liao JL, Liu N (2022) In vitro and in vivo evaluation of 211At-labeled fibroblast activation protein inhibitor for glioma treatment. Bioorg Med Chem 55:116600

    Article  CAS  PubMed  Google Scholar 

  18. Liu WH, Ma H, Liang RX, Chen XJ, Li HY, Lan T, Yang JJ, Liao JL, Qin Z, Yang YY, Liu N, Li FZ (2022) Targeted alpha therapy of glioma using 211At-labeled heterodimeric peptide targeting both VEGFR and integrins. Mol Pharm 19:3206–3216

    Article  CAS  PubMed  Google Scholar 

  19. Cai WB, Chen K, Mohamedali KA, Cao QZ, Gambhir SS, Rosenblum MG, Chen XY (2006) PET of vascular endothelial growth factor receptor expression. J Nucl Med 47:2048–2056

    CAS  PubMed  Google Scholar 

  20. Lin JL, Bent BE (1992) Carbon-halogen bond dissociation on copper surfaces: effect of alkyl chain length. J Phys Chem 96:8529–8538

    Article  CAS  Google Scholar 

  21. Glockler G (1959) Carbon-halogen bond energies and bond distances. J Phys Chem 63:828–832

    Article  CAS  Google Scholar 

  22. Olafsen T, Bruland ØS, Zalutsky MR, Sandlie I (1996) Abundant tyrosine residues in the antigen binding site in anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: application to radiolabeling. Acta Oncol 35:297–301

    Article  CAS  PubMed  Google Scholar 

  23. Nikula TK, Bocchia M, Curcio MJ, Sgouros G, Ma Y, Finn RD (1995) Impact of the high tyrosine fraction in complementarity determining regions: measured and predicted effects of radioiodination on IgG immunoreactivity. Mol Immunol 32:865–872

    Article  CAS  PubMed  Google Scholar 

  24. Olafsen T, Bruland ØS, Zalutsky MR, Sandlie I (1995) Cloning and sequencing of V genes from anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: Location of lysine residues and implications for radiolabeling. Nucl Med Biol 22:765–771

    Article  CAS  PubMed  Google Scholar 

  25. Shih YH, Peng CL, Lee SY, Chiang PF, Yao CJ, Lin WJ, Luo TY, Shieh MJ (2015) 111In-cetuximab as a diagnostic agent by accessible epidermal growth factor (EGF) receptor targeting in human metastatic colorectal carcinoma. Oncotarget 6:16601–16610

    Article  PubMed  PubMed Central  Google Scholar 

  26. van Dijk LK, Boerman OC, Franssen GM, Kaanders JH, Bussink J (2015) 111In-cetuximab-F(ab’)2 SPECT and 18F-FDG PET for prediction and response monitoring of combined-modality treatment of human head and neck carcinomas in a mouse model. J Nucl Med 56:287–292

    Article  PubMed  Google Scholar 

  27. van Dijk LK, Hoeben BA, Kaanders JH, Franssen GM, Boerman OC, Bussink J (2013) Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and 111In-labeled cetuximab-F(ab’)2. J Nucl Med 54:2118–2124

    Article  PubMed  Google Scholar 

  28. Cornelissen B, Waller A, Target C, Kersemans V, Smart S, Vallis KA (2012) 111In-BnDTPA-F3 an Auger electron-emitting radiotherapeutic agent that targets nucleolin. EJNMMI Res 2:9

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was financially supported by the National Natural Science Foundation of China (22006105), Major Science and Technology Projects of Sichuan Province (China) (2019ZDZX0004) and the China Postdoctoral Science Foundation (2020M683309).

Author information

Authors and Affiliations

  1. Department of Pathology, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, 610072, Sichuan Province, People’s Republic of China

    Zhonghui Liao, Yiwei Liu & Shunqiong Peng

  2. Key Laboratory of Radiation Physics and Technology of the Ministry of Education, Institute of Nuclear Science and Technology, Sichuan University, Chengdu, 610064, Sichuan Province, People’s Republic of China

    Zhonghui Liao, Yu Tang, Weihao Liu, Tu Lan, Jiali Liao, Yuanyou Yang, Ning Liu & Feize Li

Authors
  1. Zhonghui Liao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yu Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Weihao Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yiwei Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shunqiong Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tu Lan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jiali Liao
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yuanyou Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ning Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Feize Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Yiwei Liu or Feize Li.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liao, Z., Tang, Y., Liu, W. et al. 111In and 131I labeled nimotuzumabs for targeted radiotherapy of a murine model of glioma. J Radioanal Nucl Chem 332, 1337–1343 (2023). https://doi.org/10.1007/s10967-023-08777-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10967-023-08777-9

Keywords

Search

Navigation